Diabytes
Dilip Shanghvi News
)
Dilip Shanghvi Networth: Dilip Shanghvi, the visionary founder of Sun Pharmaceuticals, has extensive industrial experience in the pharmaceutical industry. Starting the company with just two employees focused on marketing and distributing medicines under his leadership, Shanghvi transformed Sun Pharmaceuticals into India’s most valuable listed pharma enterprise.
Today, the company generates nearly two-thirds of its reported $5.3 billion annual revenue from international markets. In 2023, Sun Pharma marked a significant milestone by completing a $576 million acquisition of the US-based Concert Pharmaceuticals, further solidifying its global footprint. Shanghvi’s business empire now generates an impressive $5.4 billion (approximately Rs 44,971 crore) in annual revenue reportedly.
)
When he started his pharma company in 1983 with 5 products and 5 people, hardly anyone could guess the success he will achieve. In 1987 when the company began selling on a national scale, it was ranked 108th. Now it ranks 6th, which is nothing short of mind-blowing.
)
Dilip Shanghvi founded Sun Pharmaceutical in 1982 in Vapi, Gujarat.
Shanghvi was born into a Gujarati family in the small village of Amreli, Gujarat.
In Kolkata, his father had a wholesale pharmaceutical business.
)
Dilip Shanghvi is the founder and managing director of Sun Pharmaceutical Industries Limited, India's most valuable listed pharma outfit.
)
NSDL on Wednesday said it has applied to the Reserve Bank for the final licence for its payments bank and is aiming to launch the entity by May.
)
India's richie rich club has shrunk by 11 people since the demonetisation last November, while Mukesh Ambani remains the richest Indian with a net worth of USD 26 billion, a study showed on Tuesday.
)
Tech Mahindra is the third applicant to abandon the plan to set up payments bank after Cholamandalam which quit last month and Dilip Shanghvi-IDFC Bank-Telenor combine last Friday.
)
A host of leaders from the business world have recieved Padma awards this year. Check out the list.
)
Sun Pharmaceutical Industries on Friday posted an over three-fold jump in its consolidated net profit at Rs 1,416.60 crore for the December quarter, driven by robust sales in domestic as well as international markets.
)
Three Indians - Mukesh Ambani, Azim Premji and Dilip Shanghvi - have made it to a global list of 50 wealthiest people that is topped by Bill Gates.
)
Business tycoon late Dhirubhai Ambani and construction magnate Pallonji Shapoorji Mistry are among industrialists chosen for this year's highest civilian awards that recognise the country's best talents.
)
The offer, that would begin on December 28 and close on January 8, 2016, comes after Shanghvi decided to acquire 23 percent stake in Suzlon with an equity investment of Rs 1,800 crore. The deal was announced earlier this year.
)
)
Drug major Sun Pharmaceutical Industries on Saturday reported 46.02 percent dip in its consolidated net profit at Rs 1,106.66 crore for the second quarter ended September 30, 2015 on account of lower sales, volatile currency movements and supply constraints.
)
Sun Pharma may discontinue certain non-strategic businesses as part of its integration process with Ranbaxy Laboratories, which it acquired in a USD 4 billion deal last year.
)
Indian pharma industry is capable of discovering at least a couple of new drugs in the next 10 years, Sun Pharmaceutical Industries founder and managing director Dilip Shanghvi said today
)
India's largest drugmaker Sun Pharma may file application for a new drug with the US Food and Drug Administration in next two to three years, the company's Managing Director Dilip Shanghvi said on Thursday.
)
Sun Pharmaceutical Industries has started easing out excess employees from Ranbaxy, including senior executives, following completion of its USD 4 billion acquisition of the Gurgaon-based firm.
)
This comes after a year after the Dilip Shanghvi-led firm acquired Ranbaxy in an all-stock deal and the company's Q4 profits shrank 44 per cent due to costs incurred in assimilating the buyout.
"We continue to remain opportunistic for acquisition... We are not looking at buying businesses where we have to spend a lot of time in managing," Sun Pharma MD Dilip Shanghvi said in an analyst call.
Loading...
 "Will Hindus get justice in Bengal's Murshidabad?")
 "DNA: Uproar over freebies in Delhi!")
 "DNA: AIMIM plans to field 2020 Delhi riots accused Shahrukh Pathan")
 "DNA: A report showing the reality of Bangladesh")
 "DNA: Power Theft Allegations Against SP MP Ziaur Rahman Barq")
 "DNA: Hot Tea Linked to Cancer Risk!")
 "DNA: Why Jordan Fears After Syria’s Coup?")
 "DNA: NSA Ajit Doval’s China Visit - Inside Story")
 "DNA: Gandhi Family Ruined My Career, says Mani Shankar Aiyar")
 "DNA: Ground Report- Tight Security Arrangements for Mahakumbh")
